- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00407472
ATS-1 Needle Free Injection Device Study-a Device for Administering r-hGH (Saizen) to Treat Growth Hormone Deficiency
This study was a Phase I, open label, randomized, 2-period, 2-sequence, crossover study designed to assess the relative bioavailability of Saizen administered by the ATS-1 needle-free injection device and a standard needle and syringe. Informed consent was obtained prior to screening. All screening assessments establishing subject eligibility were performed in the 21 days before dosing. Randomization Pre-dose on Day 1, subjects were randomized to one of the two treatment sequences: Sequence 1: SC Saizen administered by the Standard needle and syringe (Period 1) followed by the administration using the ATS-1 device (Period 2). Sequence 2: SC Saizen administered by the ATS-1 device (Period 1) followed by administration using the standard needle and syringe (Period 2).
Subjects were resident at the Unit from approximately 19:00 on Day -1 until Day 2 (approximately 30 hours (h) post dose) of each treatment period. An IV Stilamin infusion was commenced 1 h before. Saizen administration and stopped immediately after the last pharmacokinetic (PK) blood sample has been taken, i.e. a 25 h infusion. Stilamin was administered as a constant IV infusion at a rate of approximately 118 mg/h (40 mL/h), which corresponds to 1.65 mg/kg body weight/h for a person weighing 70kg. Dosing with Saizen occurred between approximately 0800 and 0900 h on Day 1 of each treatment period after an overnight fast of at least 10h. Subjects were dosed with Saizen at the same time on Day 1 in Periods 1 and 2. There was a minimum of 7-day washout between treatment periods 1 and 2.
Laboratory safety tests, ECGs were taken at protocol specified time points and blood samples for the assessment of glucose and growth hormone were taken immediately predose and 1, 2, 3, 4 4.5, 5, 5.5, 6, 7, 8, 12, 18 and 24 h post dose. A post-study visit took place 33+/- 3 days after dosing a treatment period 2.
연구 개요
연구 유형
등록
단계
- 1단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male Subjects age 21 to 50
- Have given written informed consent
- Have a body weight greater than 60 kg and a body mass index (BMI) in the range of 22 30 (BMI - weight (kg) / height (m) 2)
- Have vital signs in the following normal range:
- Oral body temperature: 35.0 - 37.5 0C
- Blood Pressure (BP): Supine BP after at least 3 minutes of supine rest Systolic BP: 90 - 150 mm Hg, diastolic P: 50 - 95 mm Hg, Supine heart rate after at least 3 minutes of rest: 40 - 90 bpm
- Be non-smoker or smoke less than or equal to five cigarettes (or use an equivalent amount of tobacco per day and be willing not to smoke whilst resident in the clinical unit
- Be able to communicate well with the Principal Investigator and be willing to comply with the requirements of the entire study
- Agree to use barrier contraception (condom and spermicide) during the study and for three months following completion of the post study visit.
Exclusion Criteria:
- Existence of any surgical or medical condition which in the opinion of the Principal Investigator might interfere with the absorption, distribution, metabolism or elimination of the investigational medicinal product or with the aims of the study
- Have any clinically significant abnormality in the results of the screening safety laboratory tests
- Have an clinically significant abnormality on the 12-lead resting ECG at screening
- Have positive results from virology examination for Hepatitis surface antigen (HBsAg) (not due to vaccination), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV 1 and 2) at screening
- History or presence of hypertension or other significant cardiovascular abnormalities
- History or presence of cholelithiasis
- Significant history or clinical evidence of auto-immune, gastrointestinal, hematological, haemaoppoietic, hepatic, neurological, pancreatic or renal disease
- History or presence of diabetes
- Definite or suspected personal history or family history of adverse drug reaction or hypersensitivity to drugs with similar chemical structure to somatotropin or somtostatin
- Use of any chronic medication
- Presence or history of any serious allergy (requiring hospitalization or prolonged systemic treatment)
- History or presence of drug or alcohol abuse. The limits of alcohol consumption for inclusion in the study are defined as an average daily intake of 3 units or a maximum weekly intake of grater than 21 units (1 unit equals 340 mL of beer, 115 mL of wine or 43 mL or spirits)
- Loss or donation or more than 400 mL of blood in the 12 weeks before dosing
- Subjects who have used any prescription drugs within 2 weeks or over-the-counter medication (with the exception of paracetamol and multi-vitamins) within 1 week before dosing without prior approval from the investigator
- Administration of any investigational drug in the 12 weeks before dosing
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 없음(오픈 라벨)
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Anthony Priestley, MBChB MFPM, Bourn Hall Clinic
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 25821 (기타 식별자: Stanford IRB)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
ATS-1 needle free device에 대한 임상 시험
-
Biruni University완전한
-
KU LeuvenUniversitaire Ziekenhuizen KU Leuven; Research Foundation Flanders완전한
-
Baim Institute for Clinical ResearchBeth Israel Deaconess Medical Center완전한
-
National Institute of Diabetes and Digestive and...Merck Sharp & Dohme LLC; Medtronic; Sanofi-Synthelabo; Diagnostic Ultrasound; Urologix종료됨
-
Fred Hutchinson Cancer Center모집하지 않고 적극적으로중증 근무력증 | 시신경 척수염 | 자가 면역 질환 | 만성 염증성 탈수초성 다발신경병증 | 램버트 이튼 근무력증 증후군 | 소뇌 변성 | 강직한 사람 증후군 | 간대성 근간대성 증후군 | 신경학적 자가면역질환 | 자가 이식 자가면역 | 다발성 경화증 이식 | MS 줄기세포 이식 | 다발성 경화증 줄기 세포 이식 | 신경학적 자가면역 질환에 대한 HCT | CIDP 이식 | 중증 근무력증 이식 | 자가면역 신경계 장애 | 중추 신경계 혈관염 | 라스무센 아급성 뇌염미국
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)완전한